Cambridge, Massachusetts, United States, December 2025 – Pooja Vatsyayan has started a new position as Vice President, Program and Commercialization Lead at Alkeus Pharmaceuticals, Inc.. In this role, she will lead the integrated global program strategy and provide strategic, cross-functional leadership for the development, registration, and commercialization of gildeuretinol in Stargardt disease, aligning clinical progress with evolving market and competitive dynamics.
In her current role at Alkeus Pharmaceuticals, Pooja Vatsyayan is responsible for orchestrating global, cross-functional plans that bridge clinical development and commercialization. Her mandate includes integrating emerging clinical data, competitive intelligence, and market insights to inform program decisions and shape a robust commercialization strategy for gildeuretinol.
Immediately prior, she served as Vice President, Head of Marketing at Alkeus Pharmaceuticals, where she drove U.S. commercial planning, ensured cross-functional alignment, designed insight-gathering strategies to identify market-readiness gaps, and developed comprehensive KOL engagement and customer segmentation approaches to enable effective brand execution.
Before joining Alkeus, Pooja Vatsyayan was Global Head – Pharmaceutical Commercial Strategy and Development at Alcon, where she led brand strategy and cross-functional launch execution for TRYPTYR (Dry Eye) and co-led pipeline program teams to ensure tight alignment between clinical development and commercialization objectives.
Earlier, she spent over four years at Apellis Pharmaceuticals, progressing from Senior Director, Global Commercial Leader – Ophthalmology to Executive Director, Global Commercial Strategy, Ophthalmology, where she spearheaded global launch readiness for SYFOVRE, the first-ever treatment for geographic atrophy, and led lifecycle management and global brand strategy.
Her career also includes senior global and U.S. commercial leadership roles at Sanofi Genzyme and Bioverativ (a Sanofi company) across hemophilia portfolios, as well as extensive experience at Biogen and Eli Lilly & Company India, where she built a strong foundation in sales, training, and brand leadership across India and global markets.
Pooja Vatsyayan has completed the Executive Programme in Business Management (EPBM) from the Indian Institute of Management Calcutta, strengthening her strategic and commercial leadership capabilities.
About Alkeus Pharmaceuticals, Inc.
Alkeus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company co-founded in 2010 with a singular mission to develop novel treatments for degenerative retinal diseases. Focused on transforming care for severe, progressive retinal conditions that cause blindness in children and adults, Alkeus is advancing innovative science aimed at preserving vision and improving quality of life.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
